Results 181 to 190 of about 142,623 (303)

Hospitalisation Is a Strong Risk Factor for Discontinuation of Sodium‐Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium–glucose cotransporter 2 inhibitors (SGLT2i) are commonly withheld during hospitalisation because of concerns about diabetic ketoacidosis. We examined whether hospitalisation was associated with discontinuation of SGLT2i and compared patterns with another anti‐hyperglycaemic medicine without similar inpatient safety concerns ...
Tamara Y. Milder   +13 more
wiley   +1 more source

Epistaxis in Patients Receiving Oral Anticoagulants and Antiplatelet: Prevalence, Risk Factors at a Tertiary Care Hospital in Nepal: A Cross-Sectional Study. [PDF]

open access: yesHealth Sci Rep
Sah SK   +9 more
europepmc   +1 more source

Antiplatelet Agents: A Review [PDF]

open access: yesJournal of the Royal Society of Medicine, 1979
openaire   +2 more sources

Initiation of SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Metformin Users and Risk of Incident Depression: A Nationwide, Claims‐Based Active‐Comparator New‐User Study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To examine the association between initiation of sodium‐glucose cotransporter‐2 (SGLT2) inhibitors and risk of incident depression compared with dipeptidyl peptidase‐4 (DPP‐4) inhibitors among adults with newly diagnosed Type 2 diabetes receiving metformin.
Sangwoo Park   +5 more
wiley   +1 more source

Haemorrhagic risk of transperineal ultrasound-guided prostate biopsy performed under continued antithrombotic therapy. [PDF]

open access: yesBJUI Compass
Akagi N   +13 more
europepmc   +1 more source

Use of Glucose‐Lowering Drugs for Type 2 Diabetes Among Danish Care Home Residents

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Care home admission often reflects frailty and limited life expectancy, potentially altering the benefit‐harm balance of glucose‐lowering drug (GLD) treatment for type 2 diabetes (T2D). Real‐world data on treatment patterns in this setting remain limited. We examined GLD use for T2D among Danish care home residents.
Hanin Harbi   +7 more
wiley   +1 more source

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

open access: yes
British Journal of Haematology, EarlyView.
Isacco Ferrarini   +19 more
wiley   +1 more source

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy